Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1980 Sep 15;46(6):1333-8.
doi: 10.1002/1097-0142(19800915)46:6<1333::aid-cncr2820460606>3.0.co;2-3.

High-dose Methotrexate With "RESCUE" Plus Cyclophosphamide as Initial Chemotherapy in Ovarian Adenocarcinoma. A Randomized Trial With Observations on the Influence of C Parvum Immunotherapy

Clinical Trial

High-dose Methotrexate With "RESCUE" Plus Cyclophosphamide as Initial Chemotherapy in Ovarian Adenocarcinoma. A Randomized Trial With Observations on the Influence of C Parvum Immunotherapy

J J Barlow et al. Cancer. .

Abstract

In a prospective randomized study, the chemotherapeutic combination of high-dose methotrexate-citrovorum factor rescue plus cyclophosphamide (MECY) has been shown to be statistically significantly superior to the combination of 5-fluorouracil plus cyclophosphamide (FUCY) in the treatment of Stage III-IV ovarian adenocarcinoma. With MECY, an overall objective remission rate of 67% and a complete remission rate of 48% were achieved. All patients had undergone no treatment except for surgery. In addition to the chemotherapy, patients were randomly allocated to receive or not receive nonspecific immunotherapy with Corynebacterium parvum; this immunotherapy had no apparent effect on the chemotherapeutic response. The study demonstrates a high degree of activity for the MECY regimen, and a comparison between the results with MECY in this study and melphalan in an earlier prospective randomized study provides statistical evidence favoring MECY over single-agent melphalan in the treatment of this disease.

Similar articles

See all similar articles

Cited by 1 article

Publication types

LinkOut - more resources

Feedback